CSL Ltd (CSL)

308.30
-3.71(-1.19%)
  • Volume:
    240,780
  • Bid/Ask:
    308.26/308.33
  • Day's Range:
    305.51 - 310.76

CSL Overview

Prev. Close
312.01
Day's Range
305.51-310.76
Revenue
19.9B
Open
310
52 wk Range
242-320.42
EPS
7.14
Volume
240,780
Market Cap
142.17B
Dividend (Yield)
1.59
(0.94%)
Average Volume (3m)
652,850
P/E Ratio
43.72
Beta
0.4
1-Year Change
3.64%
Shares Outstanding
455,671,250
Next Earnings Date
15 Feb 2022
What is your sentiment on CSL Ltd?
or
Vote to see community's results!

CSL Ltd News

  • ASX 200 Halts 2-Session Slide
    • ByInvesting.com-

    By Oliver GrayInvesting.com - The S&P/ASX 200 added 35 points or 0.47% in early trade on Friday, snapping two sessions of consecutive decline as mining companies and biotech firms...

  • ASX 200 Extends Losses at Close
    • ByInvesting.com-

    By Oliver Gray Investing.com - The S&P/ASX 200 dipped 41.4 points or 0.55% to 7485.7 on Thursday, extending losses of 0.1% in the previous session as mining stocks fell after iron...

  • ASX 200 Closes Lower As Earnings Roll On
    • ByInvesting.com-

    By Oliver GrayInvesting.com - The S&P/ASX 200 fell 8.9 points or 0.12% to 7502.1 on Wednesday, extending declines of 0.94% in the previous session as mining stocks weighed down...

CSL Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellSellBuyStrong Buy
Technical IndicatorsSellStrong SellStrong SellNeutralStrong Buy
SummarySellStrong SellStrong SellNeutralStrong Buy

CSL Ltd Company Profile

CSL Ltd Company Profile

Employees
25000
Market
Australia

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Read More
  • do I buy
    0
    • on the dip
      0
  • It can only fall so much
    0
    • Anyone knows why CSL keep dropping??
      3
      • Great! BTFD 👍🏻
        0
      • Not as strong forecasts for future earnings
        0
      • Most business in US so profits less as US dollar taking a hit, alot of the work they do has stopped since covid.
        2
    • As of 27/0220 CSL is going up after a temporary fall. Rather its an opputunity to stock up and avoid regrets. Plus exdividend next month. Have fun fellow traders and investers.
      9
      • It will go up to at least 220 ; T2: 232
        0
        • looks like it's on a downtrend when checking yearly monthly charts, I'd be looking for some pretty solid bullish reversal indicators before considering
          3
          • looks like it's on a downtrend when checking yearly monthly charts, I'd be looking for some pretty solid bullish reversal indicators before considering
            0
            • invest later when they are at their lowest
              0
              • is this good to invest in ?
                1
                • Do some research and you might find out.
                  1
              • is this good to invest in ?
                1
                • invest later when they are at their lowest
                  0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.